CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model.

"sequencing data were deposited in bioproject (accession number prjna1060736 )."

"Conflict-of-interest disclosure: P.R. and R.G. have filed a provisional patent application for the use of genetically modified cells comprising a deletion in MIR155HG to prevent GVHD; H.K.C. has served on advisory boards or consulting for Incyte, Sanofi, and Actinium and research support from Opna. The remaining authors declare no competing financial interests."

"This work was supported by the OSU Leukemia Research Program, 10.13039/100006928OSU Drug Development Institute, 10.13039/100006928OSU CCC start-up funds, 10.13039/100000002National Institutes of Health (NIH) R01CA252469, 10.13039/100000002R01HL163849, 10.13039/100000048American Cancer Society RSG RSG-22-053-01-IBCD (P.R.); 10.13039/100000002NIH T32CA090223 fellowship to K.B. and R01CA240612 (R.G.). Research reported in this publication was supported by the OSU CCC and the NIH under grant number P30 CA016058. This research was made possible through resources, expertise, and support provided by the PIIO, which is funded by the Pelotonia community and the OSU CCC."